


Truenat[®] for Sexually Transmitted Infections

Chip-based Real-Time PCR Test for
HIV-1/HIV-2, HPV-HR Plus, HSV-1/2,
CT/NG & Trich

Every day
1 million+
people acquire
an STI¹



Most remain undiagnosed, yet the consequences are real:



Infertility



Neonatal infections



Heightened HIV
susceptibility



Pelvic inflammatory
disease

With rising STI burden and growing resistance to syndromic approaches, accurate, decentralised diagnosis is more urgent than ever.

Burden

Low - and middle - income countries — especially in sub-Saharan Africa, South and Southeast Asia, and Latin America — carry the highest burden of STIs.²

WHO Diagnostic Recommendations

WHO recommends NAATs as the gold standard for STI diagnosis.

Bridging the Gap with Truenat[®] Assays for Varied STIs

HPV - HR Plus

Protect Against Cervical Cancer and Beyond.

Detects 8 high-risk HPV genotypes (16, 18, 31, 33, 35, 45, 52, 58) linked to cervical and other cancers.

96% of cervical cancer
cases are associated with
8 HR - genotypes

Early detection = Early intervention.




HIV - 1/HIV-2

For Detection & Viral Load Monitoring.

Detect early, monitor effectively, and enable timely treatment initiation—even in hard-to-reach areas.

39.9 million people live with HIV globally



HSV - 1/2

Detection of HSV - 1/2 with sensitive NAAT testing.

Clinical symptoms often overlap—lab confirmation is critical. Truenat ensures clarity and control.

Over **520 million** people (13% globally) live with HSV-2



Trichomoniasis (Trich)

Detect and Disrupt Silent Spreaders.

Asymptomatic yet impactful. Truenat detects *Trichomonas vaginalis* quickly to prevent complications like PID and enhance HIV prevention.

156 million new cases in 2020



Chlamydia & Gonorrhoea (CT/NG)

One Assay. Double Detection.

Simultaneous detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae*—two of the most common STIs globally. If left untreated Chlamydia trachomatis infection can also lead to pelvic inflammatory disease. Estimated annual cases are:

129 million
Chlamydia

82 million
Gonorrhoea

Both are often asymptomatic. Both demand sensitive, NAAT - based diagnosis.



Truenat[®] Makes STI Testing Accessible. Accurate. Actionable.

Reliable molecular diagnostics with lab-grade accuracy – brings advanced STI testing directly to the point of care.



KEY FEATURES



<1 hour turnaround time



Long shelf life

Room temperature stable reagents



User-friendly

Requires minimal human resource training



**Lyophilized, ready-to-use
PCR reagents**



Smart chip

Replete with batch-specific data



Minimal biosafety requirements

Can be used even in resource limited settings

REFERENCE

¹⁻² WHO- Updated recommendations for the treatment of *Neisseria gonorrhoeae*, *Chlamydia trachomatis* and *Treponema pallidum* (syphilis), and new recommendations on syphilis testing and partner services.



MOLBIO DIAGNOSTICS LIMITED
L-46, Phase II D, Verna Industrial Estate,
Verna, Goa - 403 722, India



+91 832-2783267



sales@molbiodiagnostics.com



www.molbiodiagnostics.com



customersupport@molbiodiagnostics.com